23andMe CEO happy to be back in business, looking toward the future
23andMe can finally take a deep breath and move forward following FDA approval, and CEO Anne Wojcicki is doing just that.
Morning Read: 23andMe releases transparency report on law enforcement data requests
Also, Versant Ventures announces investment in Turnstone Biologics and the Senate is planning a budget vote to repeal major Obamacare mandates and defund Planned Parenthood as early as November.
Using Informed Awareness to Transform Care Coordination and Improve the Clinical and Patient Experience
This eBook, in collaboration with Care Logistics, details how hospitals and health systems can facilitate more effective decision-making by operationalizing elevated awareness.
23andMe will resume providing health data following FDA setback
Following the shutdown by the FDA, 23andMe is back in business and reportedly took advantage of its two-year hiatus.
23andMe brings in $115M in Series E funding
23andMe keeps moving forward with a massive round of fundraising.
Ancestry.com joins the healthcare fray with disease-tracking AncestryHealth
Ancestry.com's first offering, AncestryHealth, helps users track their genealogical predisposition to hereditary disease, but the company plans to expand this new health division well beyond family mapping.
23andMe raises $79M following shift into drug development
23andMe recently hired Genentech veterans Robert Gentleman and Richard Scheller, who led drug discovery there.
BioLabs Pegasus Park Cultivates Life Science Ecosystem
Gabby Everett, the site director for BioLabs Pegasus Park, offered a tour of the space and shared some examples of why early-stage life science companies should choose North Texas.
Study: Customers of commercial genomic testing services understand results more than expected
For average people without a science or healthcare background, genetic testing results would seemingly be difficult to understand, but that might not be the case.
Eric Topol: Frustrated that doctors are slow to adopt pharmacogenomics
"We basically have a medical community that doesn't embrace the use of genomics," Dr. Eric Topol said. "Often times these days, it's the patients that are clamoring."
UMich’s Facebook-based genomics project emulates 23andMe – except it’s free
Emulating the 23andMe model of spit-send-sequence, a new app called Genes for Good is soliciting Facebook users to send their genetic and phenotypic data to researchers at the University of Michigan. Like 23andMe, users get to learn about their ancestry. Unlike 23andMe, it’s free. The idea is to help expand genomics research at UMich: Users are solicited via Facebook to fill out questionnaires about their […]
Allergen’s $80M fund-raise, another U.S. Ebola patient (Morning Read)
The Morning Read provides a 24-hour wrap up of everything else healthcare’s innovators need to know about the business of medicine (and beyond). The author of The Read published it but all full-time MedCity News journalists contribute to its content. TOP STORIES The NIH said it expects to admit an American patient who has tested positive for […]
presented by
A Personalized Approach to Medication Nonadherence
At the Abarca Forward conference earlier this year, George Van Antwerp, managing director at Deloitte, discussed how social determinants of health and a personalized member experience can improve medication adherence and health outcomes.
Why 23andMe launched a new therapeutics division: Unbridled power to mine genotypic & phenotypic data
Genetic testmaker 23andMe is making a smart pivot from its direct-to-consumer business: It going to start developing its own drugs. “This is a slight shift as opposed to a major change – we’re going to continue to be a direct-to-consumer company,” said Andy Page, president of 23andMe. “We’re considering the therapeutics arm as another customer of our team.” […]
How will precision medicine handle privacy concerns moving forward?
The U.S. Food and Drug Administration switched perspectives concerning patient-centric medicine on Feb. 19 when it approved the marketing of genetics testing company 23andMe’s carrier test for Bloom Syndrome – bringing it back to life after previous ethical/technical issues. Generally speaking, this was great news and demonstrates the FDA’s willingness to adapt, but there are still […]
Brace yourself for more agenda-setting conversations about personalized medicine
The ripple-effect of last week’s 23andMe news is just the beginning. A new study and an important genomics conference will only further highlight the opportunities coming in personalized medicine. New analysis from Frost & Sullivan, Future of Personalized Genomics, shows that genetic tests provided by companies straight to consumers via the e-commerce platform are more affordable […]
FDA decision allows 23andMe back in genetic testing business (but it means so much more)
23andMe can offer genetic-testing services again after the U.S. Food and Drug Administration said the California company can sell a kit to test for Bloom Syndrome, an obscure affliction that occurs when the altered gene is carried by both patents. This is a crack-in-the-dam moment – not just for 23andMe, which has been out of […]
23andMe Launches in the UK without a hitch
Here’s another thing to file in the “Europe’s a better place to launch devices and diagnostics” bucket: Controversial DNA testmaker 23andMe just made a smooth entrance into the United Kingdom market. The Food and Drug Administration made the Google-backed company pull its health-related test – which tells consumers whether they’re genetically prone to certain diseases – […]